FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Regenxbio Gets FDA Agreement to Refile Gene Therapy BLA

[ Price : $8.95]

Regenxbio reaches an agreement with FDA on a path toward a potential accelerated approval of Navsunli (clemidsogene lanparvovec-sn...

How Global Regulators Handle Cancer Drugs After FDA First Approval: Study

[ Price : $8.95]

A new journal article finds substantial differences in how major international regulators evaluate and approve oncology drugs that...

Ex-FDA Head Gottlieb Warns on Politicization Threatening Scientific Credibility

[ Price : $8.95]

Former FDA commissioner Scott Gottlieb urges federal health officials to restore scientific leadership at the agency's medical pro...

Former FDA Drug Chief Questions Future of Priority Voucher Program

[ Price : $8.95]

Former FDA Office of New Drugs director Peter Stein criticizes the agency's National Priority Voucher program at the DIA Global An...

HHS Unveils Initiative to Accelerate U.S. Clinical Trials

[ Price : $8.95]

HHS unveils a broad, department-wide initiative aimed at speeding clinical research, reducing regulatory barriers, and attracting ...

Guide on Using Quantitative Systems Pharmacology Models for Trial Dosing

[ Price : $8.95]

FDA posts a draft guidance outlining how sponsors can use quantitative systems pharmacology models to determine starting doses for...

FDA Revises Guide on Demonstrating Drug Effectiveness

[ Price : $8.95]

FDA publishes a revised draft guidance that updates how sponsors can demonstrate "substantial evidence" of effectiveness for new d...

Agency Updates Draft Guidance on Master Protocols

[ Price : $8.95]

The agency releases a revised draft guidance aimed at helping sponsors design and conduct clinical trials using master protocols, ...

FDA Regulatory Pathway Needed for Dementia Vaccine Trials: Opinion

[ Price : $8.95]

An opinion article calls on FDA to establish a formal regulatory framework for evaluating vaccines as potential interventions to p...

Merck Wins Expanded Indication for Pneumococcal Vaccine

[ Price : $8.95]

Merck says FDA has approved an expanded indication for its pneumococcal conjugate vaccine, Capvaxive, allowing its use in children...